Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $5.03 per share which missed the analyst consensus estimate of $5.07 by 0.73 percent. This is a 26.38 percent increase over earnings of $3.98 per share from the same period last year. The company reported quarterly sales of $3.190 billion which beat the analyst consensus estimate of $3.176 billion by 0.45 percent. This is a 9.55 percent increase over sales of $2.912 billion the same period last year.